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BACE1 activity impairs neuronal
glucose oxidation: rescue by
beta-hydroxybutyrate and lipoic acid
John A. Findlay †, David L. Hamilton and Michael L. J. Ashford*
Division of Cardiovascular and Diabetes Medicine, School of Medicine, Ninewells Hospital and Medical School, University of
Dundee, Dundee, UK
Glucose hypometabolism and impaired mitochondrial function in neurons have been
suggested to play early and perhaps causative roles in Alzheimer’s disease (AD)
pathogenesis. Activity of the aspartic acid protease, beta-site amyloid precursor protein
(APP) cleaving enzyme 1 (BACE1), responsible for beta amyloid peptide generation, has
recently been demonstrated to modify glucose metabolism. We therefore examined,
using a human neuroblastoma (SH-SY5Y) cell line, whether increased BACE1 activity
is responsible for a reduction in cellular glucose metabolism. Overexpression of active
BACE1, but not a protease-dead mutant BACE1, protein in SH-SY5Y cells reduced
glucose oxidation and the basal oxygen consumption rate, which was associated
with a compensatory increase in glycolysis. Increased BACE1 activity had no effect
on the mitochondrial electron transfer process but was found to diminish substrate
delivery to the mitochondria by inhibition of key mitochondrial decarboxylation reaction
enzymes. This BACE1 activity-dependent deficit in glucose oxidation was alleviated
by the presence of beta hydroxybutyrate or α-lipoic acid. Consequently our data
indicate that raised cellular BACE1 activity drives reduced glucose oxidation in a human
neuronal cell line through impairments in the activity of specific tricarboxylic acid cycle
enzymes. Because this bioenergetic deficit is recoverable by neutraceutical compounds
we suggest that such agents, perhaps in conjunction with BACE1 inhibitors, may be an
effective therapeutic strategy in the early-stage management or treatment of AD.
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Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative disease, with the vast majority of cases
described as sporadic and not currently linked with a specific gene defect. There are approximately
44million people living with AD in the world, and this number is predicted to increase dramatically
over the next three decades, severely impacting on healthcare systems and the socio-economic
environment. AD encompasses large-scale neuronal loss and progressive memory and other
cognitive decline culminating in severely impaired daily living. Indeed, there is a strong correlation
between synapse loss and cognitive deterioration (DeKosky et al., 1996; Coleman and Yao, 2003).
The neuronal cell death follows a characteristic spatial and temporal pattern; with signs of the
disease initially presenting in layer II neurons of the entorhinal cortex (EC) and spreading through
the hippocampus (Gómez-Isla et al., 1996). Selective atrophy and regional hypometabolism have
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also been shown to occur in the EC through the use of
functional imaging (Masdeu et al., 2005). Allied to this, loss
of cholinergic neurons and reduced cholinergic system enzyme
activities in the basal forebrain have been proposed to drive
early cognitive decline (DeKosky et al., 1992; Perry et al., 1992;
Geula et al., 2008). Presently, we have a limited understanding
of the molecular basis for these early events in sporadic AD
etiology. Recent proteomic analyses have however highlighted a
number of cellular processes, which become compromised. These
include the pathways of metabolism and energy production,
oxidative stress production and defense culminating in DNA
and protein modifications impacting on cytoskeletal functioning
(Sowell et al., 2009; Korolainen et al., 2010). All of these
changes culminate in alterations in synaptic communication
and precipitate memory loss (Forero et al., 2006). It has been
hypothesized that a major driver of these changes is the aberrant
folding and phosphorylation of the microtubule associated
protein tau and aggregation of β-amyloid (Aβ) peptides (Kawaja,
2005). While the progression of AD is closely associated with
dysfunctional tau protein and cholinergic deficits, it is generally
observed by biomarker and other analyses that changes in
the hallmark amyloid plaque pathology precedes these other
pathogenic drivers (Shankar et al., 2009; Jack et al., 2013a,b;
Knopman et al., 2013; Martiskainen et al., 2015). There has
also been increasing interest in the role of brain mitochondrial
dysfunction and reduced metabolic activity (Yao et al., 2009;
Swerdlow et al., 2014; Wilkins et al., 2014).
It has long been recognized that glucose is the predominant
substrate utilized by the adult brain under physiological
conditions (Bouzier-Sore et al., 2006). Indeed, while only
constituting 2% to body weight, the brain consumes around 20
and 25% of the total body oxygen consumption and glucose
respectively, (McKenna et al., 2006). Furthermore, the respiratory
quotient of the brain is almost exactly 1, indicating near
universal carbohydrate metabolism (Sokoloff, 1999). Although
glucose is the dominant substrate for brain metabolic activity,
alternative substrates, such as glycogen and amino acids can play
a role in central metabolism. However, due to limited supply
and storage capacity, this is thought to be relatively minor
under physiological conditions (Henderson et al., 2009). Glucose
metabolism in the brain is tightly coupled to the generation of
intracellular adenosine triphosphate (ATP), largely to support
neurotransmitter production and release. Consequently, this
reliance on glucose coupled with a high-energy consumption
makes the brain, and synaptic transmission in particular,
vulnerable to events, which lead to diminished metabolism.
Brain hypometabolism is a universal change observed during
Alzheimer’s disease (AD) progression and recently, it has been
proposed to have a major causative role in AD pathogenesis
(Blass, 2001; Costantini et al., 2008). Through the use of
neuroimaging techniques, impaired brain glucose metabolism
has been demonstrated to occur: before atrophy in autosomal
AD cases, during the progression toward non-familial AD and
in individuals at high risk of AD (i.e., APOE ε4 carriers) prior
to symptom manifestation (Small et al., 1995; Johnson et al.,
2001; Reiman et al., 2004; Mosconi et al., 2009a,b). This reduced
brain glucose metabolism has been postulated to result from
impaired mitochondrial functioning (Lustbader et al., 2004; Beal,
2005; Bubber et al., 2005), with similar changes observed in a
variety of transgenic mouse models of AD (von Kienlin et al.,
2005; Yao et al., 2009, 2011; Nilsen et al., 2014). Recent evidence
suggests a putative link between neuronal glucose metabolism
and the presence of Aβ peptides, considered by many to be
the primary pathogenic driver of AD. Aβ peptides derive from
increased cleavage of amyloid precursor protein (APP), which
is ubiquitously expressed in tissues, with highest levels in the
brain. APP is cleaved by two competing enzyme processes; an
alpha secretase pathway, resulting in the soluble cleaved product
sAPPα and no Aβ production and a beta secretase pathway,
which releases sAPPβ and following additional cleavage of the
remaining protein by γ-secretase, releases Aβ. Aβ accumulates
in the mitochondria of AD patients and AD mouse models,
prior to the appearance of amyloid deposits (Hirai et al., 2001;
Devi et al., 2006; Manczak et al., 2006). Indeed, exogenous Aβ
has been reported to decrease mitochondrial respiratory chain
function and the activity of variousmitochondrial dehydrogenase
enzymes (Shearman et al., 1994; Casley et al., 2002a; Pereira
et al., 2004; Caspersen et al., 2005), indicative of an Aβ-mediated
bioenergetic deficit in cells.
Additionally, it has been shown that the hypometabolic
state associated with AD may be driven, at least in part, by
a region-specific shift in neuronal metabolism toward aerobic
glycolysis (reduced oxidative metabolism in the presence of
adequate oxygen supply; Vaishnavi et al., 2010). This switch
in glucose metabolism was shown to closely correlate with Aβ
deposition and later vulnerability to cell death during progression
toward AD (Vlassenko et al., 2010). These findings clearly
implicate the modulation of APP processing as a driver of the
altered metabolic state observed in early, pre-AD states. A key
enzyme driving excess Aβ production, as observed in AD, is
the aspartyl protease, β-site APP cleaving enzyme 1 (BACE1).
BACE1 was initially characterized as the enzyme controlling
the rate-limiting step in Aβ generation (Hussain et al., 1999;
Sinha et al., 1999; Vassar et al., 1999). More recently however,
it has also been proposed to play a role in glucose metabolism
with whole body knock out of BACE1 resulting in improved
insulin sensitivity and glucose homeostasis (Meakin et al., 2012).
Furthermore, genetic and pharmacological manipulation of APP
processing can directly alter glucose uptake and metabolism
in the C2C12 skeletal muscle cell line (Hamilton et al., 2014).
Importantly, BACE1 is a stress-sensitive protease, with oxidative,
hypoxic, inflammatory, and metabolic stress (all associated with
AD initiation and/or progression) demonstrated to increase
BACE1 levels and activity, causing APP processing to shift from
the physiologically predominant alpha-secretase, to the beta-
secretase, pathway, and increasing Aβ levels. Indeed, recent
work has demonstrated a role for oxidative, lipid and metabolic
stressors in regulating BACE1 gene and protein expression as well
as activity (Puglielli et al., 2003; Velliquette et al., 2005; Zhang
et al., 2007; O’Connor et al., 2008; Guglielmotto et al., 2009).
Furthermore, alterations in its expression result from changes in
micro RNA (miR) regulation of the 5′ untranslated region (UTR)
of BACE1 have been demonstrated in sporadic AD cases (Nelson
andWang, 2010; Fang et al., 2012; Lei et al., 2015). Consequently,
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chronic stress events and altered translational regulation may
in turn culminate in the consistent reports that BACE1 mRNA,
protein and activity are elevated in AD brains (Fukumoto et al.,
2002; Holsinger et al., 2002; Tyler et al., 2002; Yang et al., 2003; Li
et al., 2004; Harada et al., 2006; Zhao et al., 2007).
Given that Aβ directly impairs mitochondrial enzyme
function and that AD is associated with impaired glucose
metabolism we hypothesized that manipulating APP
processing through BACE1 overexpression in SH-SY5Y
neuroblastoma cells would phenocopy the defects in glucose
metabolism at the cellular level, allowing us to explore in
more detail this initial and potentially causative change in AD
progression.
Materials and Methods
Cell Culture
SH-SY5Y cells were cultured under aseptic conditions and
maintained in a humidified atmosphere of 95% air and 5%
CO2. Cells were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) F-12 media (Gibco Life Technologies,
Paisley, UK) supplemented with 10% fetal bovine serum (Sera
Laboratories, West Sussex, UK), 4mM L-glutamine (Gibco) and
2% Penicillin streptomycin (100 units/ml; Gibco). SH-SY5Y cells
were transfected with 12µg DNA of pcDNA3.1 containing empty
vector (SH-SY5YEV), full-length human BACE1 (SH-SY5YB1), or
BACE1 active site mutant (SH-SY5YmB1) using Lipofectamine
2000 (Invitrogen Life Technologies, Paisley, UK). Stable cells
were selected and lines maintained using 1 and 0.5mg/ml
G418 sulfate respectively, (Sigma-Aldrich, Gillingham, UK) as
selection antibiotic. A minimum of two independently generated
stable cell lines, with concurrently produced EV controls, were
used for these studies. Prior to some glucose oxidation assays,
cells were treated overnight, as indicated, with the pyruvate
dehydrogenase inhibitor, dichloroacetate (DCA; Sigma-Aldrich)
or growth media supplemented with α-lipoic acid (Sigma-
Aldrich) for 48 h.
Cloning
Full length myc-his tagged human BACE1 in pcDNA3.1
was obtained from GlaxoSmithKline (GSK; Harlow, UK)
and mBACE1 (a kind gift from Professor Wolfe (Brigham
and Women’s Hospital, Boston)) was sub-cloned into
pcDNA3.1.
Immunoblotting and Gene Expression
Protein isolation and immunoblotting procedures were as
described previously (Mirshamsi et al., 2004). For relative
quantification of APP cleavage by alpha-secretase (sAPPα)
vs. beta-secretase (sAPPβ) pathways, cells were incubated
for between 20 and 24 h in Optimem (Gibco), and media
concentrated (using 30 kDa Amicon Ultra 15ml filters; Merck
Millipore, Livingston, UK) by centrifugation (4000 × g) and
subjected to SDS-PAGE with amounts presented relative to
total protein. Protein antibodies used were: anti-Actin (Sigma-
Aldrich; 1:5000), anti-APP (Ab54, GSK; 1:4000), anti-sAPPα
(Cambridge Bioscience, Cambridge, UK; 1:1000), anti-sAPPβ
(GSK; 1:1000), anti-BACE1 (Sigma-Aldrich; 1:1000), anti-BAD
(New England Biolabs, Hitchin, UK; 1:1000), with anti-total PDH
(1mg/ml) and anti-pPDHe1α (1mg/ml) from Drug Discovery
Unit, University of Dundee.
Glucose Oxidation Assay
SH-SY5YEV, SH-SY5YB1, or SH-SY5YmB1 cells were plated into
6-well cell culture plates and any pre-treatments carried out as
described above and in the Results Section. To begin the assay,
cells were washed twice with Hepes-buffered saline (HBS (in
mM); 140 NaCl, 20 Hepes, 5 KCl, 2.5 MgSO4, and 1 CaCl2,
pH 7.4) and incubated in HBS containing 2.5mM glucose
and 74 kBq/ml D-[U-14C]glucose (PerkinElmer) along with
any relevant inhibitors or treatments indicated in the Results
Section for 3 h at 37◦C. Media were transferred and 14CO2
liberated by acidification with 60% perchloric acid, trapped by
Whatman (GF/B) filter paper discs pre-soaked with 1M KOH
and radioactivity quantified by liquid-scintillation counting. Cells
from the assay were washed twice with ice-cold 0.9% NaCl
and lysed with 1ml of 50mM NaOH, and the radioactivity
contained within the lysate quantified by liquid-scintillation
counting, which served as a measure of the 14C incorporation
into the cell during the assay period. Total protein content was
determined in the lysate via the Bradford method and used to
normalize glucose incorporation and oxidation rates for each
sample.
Cellular Respiration
The Seahorse Extracellular Flux Analyser utilizes solid sensors
that simultaneously monitor the oxygenation and pH of the
media. The rate of oxygen consumption (OCR) and extracellular
acidification rates (ECAR) can therefore be assessed in near
real time allowing for high resolution changes in a range
of metabolic parameters. SH-SY5YEV, SH-SY5YB1, or SH-
SY5YmB1 cell monolayers were seeded into XF 24-well culture
microplates (Seahorse Bioscience, Copenhagen, Denmark) the
day prior to treatment or assay as indicated in the Results
Section. Optimal cell number was determined following a
cell titration assay taking into account oxygen consumption
rate (OCR) and extracellular acidification rate (ECAR), oxygen
tension values and the appearance of the cell monolayers
and was determined to be 40,000 cells. On the day of the
assay, cells were placed in unbuffered DMEM with relevant
inhibitors/treatments as indicated and placed in a non-CO2
incubator for 1 h (to de-gas solutions) prior to assay initiation.
Standard 3min mix, 2min wait, and 3min measure cycles
were used; with five baseline measurements taken before, and
a subsequent three measurements acquired following, drug
additions.
Enzyme Activity Assays
Activity assays for pyruvate dehydrogenase (PDH; Abcam,
Cambridge, UK), α-ketoglutarate dehydrogenase (α-KGDH;
Antibodies Online, Aachen, Germany), isocitrate dehydrogenase
(IDH; Sigma-Aldrich), and fumarase (Abcam) were performed
according to the manufacturer’s instructions.
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Results
Overexpression of BACE1 Increases
Amyloidogenic APP Processing and Suppresses
Glucose Oxidation
Control, empty vector-treated (SH-SY5YEV) and BACE1
overexpressing (SH-SY5YB1) cells displayed equivalent APP
protein levels, showing the three predominant APP transcript
protein isoforms present in neurons (Huang and Jiang,
2011; Figures 1A,B). As expected, SH-SY5YB1 cells exhibited
significantly higher BACE1 protein levels (Figures 1A,C),
which resulted in altered APP cleavage; promoting a substantial
shift from non-amyloidogenic to amyloidogenic processing
(as denoted by increased sAPPβ and decreased sAPPα levels
(Figures 1A,D,E). Overexpression of BACE1 resulted in a
marked reduction in the rate of 14C-glucose oxidation, compared
to SH-SY5YEV cells (Figure 1F), in agreement with recent
findings in C2C12 skeletal muscle cells (Hamilton et al., 2014).
The decrease in glucose oxidation is not due to impaired glucose
incorporation into the cell (Figure 1G), and suggests that
increased BACE1 protein levels and activity cause a fundamental
change in the ability of SH-SY5Y cells to oxidize glucose
(Figure 1H).
In an attempt to discern whether the changes in glucose
oxidation rate were dependent upon the secretase activity of
BACE1, a concomitant group of cells that overexpress a mutant
form of BACE1, devoid of secretase activity (SH-SY5YmB1;
Mowrer and Wolfe, 2008) were examined. BACE1 protein levels
in SH-SY5YmB1 cells were raised to a similar extent to that
observed for SH-SY5YB1 cells, with no alteration in APP protein
levels (Figures 2A–C). Interestingly, the overexpression of the
secretase-dead BACE1mutant exerted a dominant negative effect
over APP processing with reduced sAPPβ release, compared
with SH-SY5YB1 and SH-SY5YEV cells, into the culture media
(Figures 2A,D). The reduced β-secretase cleavage of APP in
the presence of mBACE1 was also mirrored in its effect on
glucose oxidation rate, with no reduction in glucose oxidation
concomitant with comparable glucose incorporation between cell
types (Figures 2E,F), indicating that increased BACE1 activity
is required to depress glucose oxidation in SH-SY5Y cells
(Figure 2G).
Chronic Elevation of BACE1 Stimulates Aerobic
Glycolysis in SH-SY5Y Cells
The cellular pathways that facilitate glucose metabolism are
glycolysis (and the pentose phosphate pathway), which occurs in
the cytoplasm and the TCA cycle and oxidative phosphorylation,
which are present in the matrix and inner mitochondrial
membrane, respectively. Actively respiring mitochondria
consume oxygen and therefore oxygen consumption rate (OCR)
FIGURE 1 | BACE1 overexpression alters APP processing and glucose oxidation in SH-SY5Y cells. (A) Representative immunoblots showing stable
overexpression of BACE1 and resultant changes in cellular APP and sAPPα and sAPPβ shed into the culture media, compared to empty vector (EV) treated controls.
(B–E) SH-SY5Y BACE1 overexpression did not change APP protein levels (B; n =4), increased total BACE1 protein levels (C; n = 7) and induced a shift in APP
processing, with a reduction in sAPPα (D; n = 4) and an increase in sAPPβ (E; n = 4). (F–H) SH-SY5Y BACE1 overexpression reduced 14C-glucose oxidation rate (F;
n = 7), with no reduction in 14C-glucose incorporation rate (G; n = 9), giving an overall reduction in the ratio of 14C-glucose oxidation to incorporation (H; n = 7).
Values are means ± SEM. **p < 0.01; ***p < 0.001.
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FIGURE 2 | Glucose oxidation in SH-SY5Y cells in not impaired following overexpression of secretase-dead BACE1 protein. (A) Representative
immunoblots showing stable overexpression of wild type BACE1 and a secretase-dead BACE1 mutant (mBACE1) and resultant changes in cellular APP and sAPPβ
shed into the culture media. (B–D) SH-SY5Y mBACE1 overexpression increased total BACE1 to levels equivalent to BACE1 overexpressed cells and ∼3-4X greater
than empty vector (EV) controls (B; n = 5), with no effect on APP levels (C; n = 3), but in contrast to BACE1 overexpression, mBACE1 reduced sAPPβ to levels below
that of the EV controls (D; n = 6–10). (E–G) SH-SY5Y mBACE1 overexpression had no effect on 14C-glucose oxidation compared to EV controls, in contrast to the
reduction in 14C-glucose oxidation observed in BACE1 overexpressing cells (E; n = 5), with mBACE1 having no effect on 14C-glucose incorporation (F; n = 5),
resulting in the ratio of 14C-glucose oxidation to incorporation being unchanged in mBACE1 cells (G; n = 5). Values are means ± SEM. *p < 0.05; **p < 0.01;
***p < 0.001.
can be taken as a measure of substrate flux through the oxidative
phosphorylation pathway while extracellular acidification rate
(ECAR) reflects the release of lactate (lactic acid) converted
from pyruvate following glycolysis. SH-SY5YB1 cells exhibit
decreased OCR concurrent with increased ECAR in comparison
to SH-SY5YEV cells (Figures 3A,B). Taken together these
changes reflect a robust shift between these metabolic processes
as shown by the change in the ratio of oxidative phosphorylation
to glycolytic metabolism in cells with increased BACE1 activity
(Figure 3C).
To further investigate these changes, a glycolysis stress
test (which assesses basal glycolysis, glycolytic capacity and
glycolytic reserve) was performed (Figure 3D). SH-SY5YEV
and SH-SY5YB1 cells were incubated in media containing
zero glucose, 2.5mM pyruvate and 4mM L-glutamine for
100min, following which stimulation of basal glycolysis was
achieved by the injection of 2.5mM glucose into the assay
media. The increase in basal ECAR was significantly higher
in SH-SY5YB1 cells, compared to control cells, indicating
that the raised BACE1 activity augmented aerobic glycolysis
(Figure 3E). Inhibition of F1F0 ATP synthase by oligomycin
leaves cells wholly reliant on glycolysis for ATP generation
(termed maximal glycolysis). This rate was also significantly
increased in SH-SY5YB1, compared to control, cells following
BACE1 overexpression (Figure 3F). Finally, the cellular
glycolytic reserve is given by the difference between basal and
maximal glycolysis, with a significantly higher glycolytic reserve
observed in the SH-SY5YB1 cells (Figure 3G). Collectively,
these data indicate that raised BACE1 activity depresses
glucose oxidation in SH-SY5Y cells and, as a result, there is a
compensatory increase in glucose metabolism through aerobic
glycolysis.
Mitochondrial Efficiency is Unaltered by Raised
BACE1 Activity in SH-SY5Y Cells
The marked reduction in oxidative phosphorylation, concurrent
with increased glycolytic metabolism in SH-SY5YB1 cells,
indicated that increased BACE1 activity reduced substrate
delivery to the mitochondria and/or impaired mitochondrial
function. To test mitochondrial efficiency in these cells,
a modified Mitochondrial Stress Test (Seahorse Bioscience)
protocol was utilized. As previously reported, a limited maximal
respiration rate is achievable in undifferentiated SH-SY5Y cells
(Xun et al., 2012) in the absence of pyruvate in the assay
media. Consequently, we therefore performed a split assay to
investigate the effects of mitochondrial metabolism perturbation:
the first part measuring the proportion of respiration dedicated
to ATP generation (ATP synthase inhibition with oligomycin),
the maintenance of mitochondrial leak (a combination of
rotenone (complex I inhibition) and antimycin A (complex
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FIGURE 3 | BACE1 overexpression alters glucose metabolism in SH-SY5Y cells. (A–C) BACE1 overexpression reduces oxygen consumption rate (OCR) (A)
and increases the extracellular acidification rate (ECAR) (B) resulting in a reduced OCR:ECAR ratio (C), compared to EV cells (n = 7–12). (D) Glycolysis stress test
temporal profile for EV and BACE1 SH-SY5Y cells showing the effects on ECAR of the sequential addition of 2.5mM glucose, 1µM oligomycin (Oligo) and 25mM
2-deoxyglucose (2DG). (E–G) BACE1 overexpression increased basal glycolysis (E), maximal glycolysis (F) and glycolytic reserve (G) compared to EV-treated cells
(n = 18–21). Values are means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
III inhibition) to minimize mitochondrial respiration) and the
relative contribution of non-mitochondrial OCR (Figure 4A).
However, increased BACE1 activity in SH-SY5Y cells had no
effect on any of these oxidative parameters (Figures 4B–D).
The second part encompasses a test of the cellular reserve
capacity via the induction of maximal respiration through
addition of the proton ionophore FCCP. This drug collapses
the mitochondrial membrane potential, leading to uncoupled
(no ATP generation) substrate flux through the mitochondria,
promoting an increase in glycolysis in an attempt to maintain
intracellular ATP levels. Raised BACE1 activity also had no effect
on SH-SY5Y mitochondrial reserve capacity (Figures 4E,F). The
results from these assays show that chronic elevation of BACE1
protein expression and activity does not impair mitochondrial
electron transfer function. Consequently, this result strongly
indicated that the BACE1 activity-driven decrease in glucose
oxidation was the result of diminished substrate delivery to the
mitochondria.
Raised BACE1 Activity Lesions Key Metabolic
Pathways in Oxidative Glucose Metabolism
There are three key control points involved in the regulation
of neuronal metabolism, these are the generation of glucose-
6-phosphate, pyruvate and acetyl CoA. In neurons, pyruvate is
predominantly produced directly from metabolism of glucose or
indirectly, through the provision of extracellular lactate via the
astrocyte-neuron lactate shuttle (Magistretti and Pellerin, 1999;
Itoh et al., 2003). Therefore, in an attempt to better understand
the changes in cellular metabolism induced by increased BACE1
activity, lactate utilization by SH-SY5Y cells was assessed. SH-
SY5YB1 cells displayed significantly reduced lactate consumption
as assessed by the ability of lactate to repress 14C-labeled glucose
oxidation (Figure 5A). This deficit could also be observed as
a reduction in OCR when cells were provided physiological
concentrations (0.5 or 2mM; Phypers and Pierce, 2006) of lactate
as sole substrate, although the reduction in lactate metabolism
was overcome by the presentation of a higher (4mM) lactate
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FIGURE 4 | BACE1 overexpression has no effect on ATP-linked,
maximal or leak mitochondrial oxygen consumption. (A) Modified
mitochondrial stress temporal profile for EV and BACE1 SH-SY5Y cells
showing the effects on the percentage change in normalized OCR of the
sequential addition of 1µM oligomycin (oligo) and 2µM rotenone and
antimycin (Rot + Ant). (B–D) BACE1 overexpression had no effect on
ATP-linked OCR (B), on the OCR required to maintain the mitochondrial leak
(C) or the non-mitochondrial OCR (D) compared to EV cells (n = 8). (E)
Temporal profile showing the normalized baseline OCR for EV and BACE1 cells
and the maximal OCR (reserve capacity) attained following addition of 0.2µM
carboyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP). (F) BACE1
overexpression has no effect on the percentage OCR increase following FCCP
addition compared to EV cells (n = 9–10). Values are means ± SEM.
concentration (Figures 5A,B). As the oxidation of both glucose
and lactate was diminished, we hypothesized that raised BACE1
activity resulted in impairment of the pyruvate dehydrogenase
complex activity (PDH). To address this we used an indirect
PDH activity assay and demonstrated that SH-SY5YB1 cells
displayed a marked reduction of PDH activity (Figure 5C).
Consistent with this outcome, SH-SY5YB1cells displayed reduced
OCRwhen provided with pyruvate (2.5mM) as the sole substrate
(Figure 5D).
In response to cellular injury or stress, compensatory
metabolic strategies are employed in an attempt to bypass
reduced glucose utilization associated with decreased PDH
activity and obviate impaired mitochondrial TCA function. For
example, glutamine metabolism is diverted from an oxidative to
reductive route (Wise et al., 2011; Mullen et al., 2012), causing
increased conversion to glutamate and, through glutamate
dehydrogenase, raised levels of α-ketoglutarate. This additional
source of α-ketoglutarate should supplement ATP generation
through the TCA cycle as it bypasses the block at PDH.
Consequently, we examined whether such an alternative route for
TCA substrate replenishment was capable of recovering oxidative
metabolism. Thus, OCR and ECAR were measured when SH-
SY5YEV and SH-SY5YB1 cells were provided glucose (2.5mM)
alone or glucose (2.5mM) + glutamine (4mM). However, the
presence of glutamine did not affect the attenuation of OCR
or enhancement of ECAR in SH-SY5YB1 cells (Figure 5E).
Moreover, OCR was reduced in SH-SY5YB1 cells when glutamine
was provided as the exclusive substrate (Figure 5F). These
data indicate that either glutamine does not play a significant
role in SH-SY5Y basal metabolism and/or that raised BACE1
activity blunts additional TCA enzymes, such as α-ketoglutarate
dehydrogenase (α-KGDH), which converts α-ketoglutarate to
succinyl-CoA. Indeed, SH-SY5YB1 cells showed a large, BACE1
secretase activity-dependent, reduction in α-KGDH activity,
which is a rate controlling step of the TCA cycle (Figure 5G).
Because, PDH and α-KGDH catalyze decarboxylation
reactions involved in mitochondrial bioenergetics, we assayed
the activity of the third enzyme utilizing this process, isocitrate
dehydrogenase (IDH). Three isoforms of IDH are present
in cells, IDH3 in the mitochondrial matrix, which reduces
NAD+ to NADH, and IDH1 (cytoplasmic and peroxisomal)
and IDH2 (mitochondrial) reducing NADP+ to NADPH.
Consequently, specific isoform function was determined by
differential supplementation (NAD+ or NADP+) of the reaction
mixes. In agreement with the results for the decarboxylation
enzymes above, raised BACE1 activity resulted in depression
of NAD+- and NADP+-dependent IHD activity (Figure 5H).
However, impairment of TCA cycle enzyme activities by
increased BACE1 activity was not universal. For example,
although fumarase activity was reduced slightly in SH-SY5YB1
cells, this was matched in SH-SY5YmB1 cells, with the protein
levels of fumarase also decreased in both these cell lines, resulting
in unaltered specific activity of fumarase by raised BACE1 in
SH-SY5Y cells (Figure 5I). Thus, manipulation of APP cleavage
toward amyloidogenic processing by increased BACE1 activity in
SH-SY5Y cells reduces the overall catabolic capacity of the TCA
cycle through specific enzyme lesions rather than a wholesale
down-regulation.
Rescue of Glucose Oxidation in SH-SY5YB1 Cells
As glutamine supplementation was unable to recover BACE1-
mediated inhibition of glucose oxidation, we focused on
PDH as a potential target for pharmacological or alternative
nutrient interventions. A key regulator of PDH activity is
by phosphorylation of its E1α subunit (Patel et al., 2014),
which is predominantly controlled by the inhibitory effect of
pyruvate dehydrogenase kinases (PDKs) vs. activation through
de-phosphorylation by pyruvate dehydrogenase phosphatase
(PDP). Dichloroacetate (DCA) is a PDK1 inhibitor, which
enhances oxidative phosphorylation in the brain (Itoh et al.,
2003) and has been promoted clinically for its anti-neoplastic
effects (Kankotia and Stacpoole, 2014). Consistent with PDH
inhibition, SH-SY5YB1 cells exhibited increased phosphorylation
of the e1α subunit at serine 293 compared to SH-SY5YEV cells
(Figure 6A). Treatment with DCA (10 and 100µM) resulted
in decreased levels of Ser293 e1α phosphorylation of both SH-
SY5Y cell types, although Ser293 e1α phosphorylation remained
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FIGURE 5 | BACE1 overexpression induces specific mitochondrial TCA cycle enzyme lesions. (A,B) SH-SY5Y cells overexpressing BACE1 exhibit reduced
lactate usage at levels ≤ 2mM compared to EV cells as demonstrated by (A) reduced repression of 14C-glucose oxidation (n = 6) and (B) direct OCR when lactate
provided as sole substrate (n = 6–11). (C) Pyruvate dehydrogenase activity (PDH) is reduced in BACE1 overexpressing, compared to EV, cells (n = 5). (D) OCR when
EV and BACE1 cells provided 2.5mM pyruvate as sole substrate (n = 5). (E) OCR of EV and BACE1 SH-SY5Y cells when provided with 2.5mM glucose alone or
2.5mM glucose + 4mM glutamine (n = 4–10). (F) direct OCR when 4mM glutamine provided as sole substrate (n = 8). (G) BACE1, but not mBACE1,
overexpression, reduced the enzyme activity of α-KGDH, compared to EV cells (n = 6). (H) IDH activity (NAD+ and NADP+ isoforms) is reduced by BACE1
overexpression compared to EV cells (n = 4). (I) BACE1 or mBACE1 overexpression has no effect on fumarase enzyme activity, protein levels or specific activity
compared to EV cells (n = 7). Values are means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
significantly higher in SH-SY5YB1 cells (Figures 6A,B). In
agreement with the reduction in e1α phosphorylation, incubation
of SH-SY5YEV cells with DCA (100µM) increased the glucose
oxidation rate (Figure 6C). However, although glucose oxidation
of SH-SY5YB1 cells was also enhanced by DCA treatment, this
remained significantly lower than that of the SH-SY5YEV cells,
mirroring e1α phosphorylation status.
An alternative means of bypassing PDH is through the
application of ketones, such as beta-hydroxybutyrate (BHB),
which is metabolized to acetyl-CoA and enters the TCA cycle
at oxaloacetate. The presence of BHB (0.5–10µM) recovered the
relative deficit in glucose oxidation of SH-SY5YB1 cells, compared
to SH-SY5YEV cells, in a concentration-dependent manner
(Figure 6D). Previous studies (Danial, 2008; Giménez-Cassina
et al., 2012) have indicated that diminished mitochondrial
consumption of glucose in neurons and the ability to switch
substrate preference to ketones is dependent on the presence
and activity of BAD (BCL-2-associated agonist of cell death), a
member of the BCL-2 gene family member of apoptotic control
proteins, with increased mitochondrial usage of BHB in Bad−/−
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FIGURE 6 | Reversal of BACE1 mediated impaired glucose oxidation in SH-SY5Y cells. (A,B) Representative immunoblots (A) of phosphorylated PDHe1α
(p-PDHe1α) subunit, total PDHe1α and actin loading control in control (EV) and BACE1 overexpressing cells in the absence and presence of 10µM or 100µM
dichloroacetate (DCA), with quantification of the immunoblot data shown in (B) (n = 4). (C) DCA partially reverses BACE1 mediated impairment of glucose oxidation,
but also increases OCR of EV cells (n = 5). (D) reduced OCR associated with BACE1 cells is recovered to EV control levels by addition of 1µM and 10µM beta
hydroxybutyrate (n = 4–6). (E) Representative immunoblots of BCL-2-associated agonist of cell death (BAD) and actin loading control with quantification of the
immunoblot data (n = 4). (F) BACE1-mediated reduction in OCR is recovered to EV control levels by addition of 50µM α-lipoic acid (n = 6). Values are means ± SEM.
*p < 0.05; **p < 0.01; ***p < 0.001.
cortical neurons. In agreement with this model, we find that
the increased ability of SH-SY5YB1 cells to utilize BHB over
SH-SY5YEV cells and enhance glucose oxidation, is associated
with a large reduction of BAD protein expression (Figure 6E).
Finally we also investigated the ability of the naturally occurring
enzyme co-factor, α-lipoic acid to modify glucose oxidation of
SH-SY5YB1 cells as previous studies have shown this compound
to up-regulate mitochondrial bioenergetics and promote glucose
uptake (Packer and Cadenas, 2011; Sancheti et al., 2013). Indeed
PDH and α-KGDH protein complexes require α-lipoic acid as
a co-factor for their acyl transferase activity. Supplementation
of the growth media with α-lipoic acid (25 or 50µM for 48 h)
resulted in a robust concentration-dependent attenuation of
the impaired glucose oxidation rate displayed by SH-SY5YB1,
compared to SH-SY5YEV cells (Figure 6F). Taken together,
these results demonstrate the applicability of alternative nutrient
(BHB) or co-factor (α–lipoic acid) supplementation to alleviate
or by-pass the impaired glucose metabolism elicited by raised
BACE1 activity in SH-SY5Y cells.
Discussion
In this study we demonstrate that raised BACE1 activity
by overexpression in SH-SY5Y cells, and subsequent
modification of APP metabolism, induces a shift from the
physiologically predominant alpha-secretase cleavage pathway
to the amyloidogenic beta-secretase cleavage pathway, which
results in decreased glucose metabolism. This bioenergetic
impairment was dependent upon the secretase activity of BACE1
and produced a fundamental shift in the cellular metabolic
profile, characterized by reduced glucose oxidation in association
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with a compensatory increase in glycolysis, in an attempt to
maintain ATP production.
Decreased brain glucose metabolism is an invariant
pathophysiological event occurring in AD progression, and it has
been hypothesized that this may occur years, and even decades
prior to symptom presentation (Mosconi et al., 2009a,b; Bateman
et al., 2012; Jack et al., 2013c). Impaired glucose metabolism
has also been noted in central tissues taken from AD animal
models (von Kienlin et al., 2005; Sancheti et al., 2013; Nilsen
et al., 2014). Furthermore, despite the observation that reduced
glucose metabolism is predictive of later cognitive decline and
AD symptom presentation, relatively little is known about the
cellular mechanisms underlying these changes. Interestingly, the
metabolic shift we have observed in favor of aerobic glycolysis
under conditions of increased BACE1 activity mirrors early and
predictive changes occurring in the brains of people who later
develop AD. The brain areas that display this profile overlap with
regions showing the greatest prevalence of Aβ pathology, future
susceptibility to cell death and are predictive of cognitive decline
(Vaishnavi et al., 2010; Vlassenko et al., 2010).
The mechanisms underlying glucose hypometabolism in AD
are not well-understood. However, mitochondrial dysfunction
has been widely reported in clinical and experimental AD studies
(Lustbader et al., 2004; Beal, 2005; Bubber et al., 2005) and Aβ has
been reported to accumulate in the mitochondria of AD patients
and transgenic AD mouse models prior to amyloid deposition
(Hirai et al., 2001; Devi et al., 2006; Manczak et al., 2006; Du
et al., 2008). Although there are numerous reports of impaired
electron transfer in mitochondria, for example via diminished
activity in complexes I to V in AD subjects (Parker et al., 1994;
Maurer et al., 2000; Kim et al., 2001; Bosetti et al., 2002), and
diminished complex III and IV activity in a transgenic AD
mouse model (Mucke et al., 2000) we found no effect of raised
BACE1 activity on mitochondrial electron transfer function in
SH-SY5Y cells. It may be that additional injurious processes, such
as increased oxidative and/or inflammatory stress are required to
act concurrently with raised BACE1 activity and increased levels
of Aβ to elicit this outcome.
Thus the driving force for decreased glucose oxidation in SH-
SY5YB1 cells appears to be through reduced substrate delivery
to mitochondria by a BACE1 activity-dependent impairment
of specific TCA cycle enzymes; PDH, αKGDH and IDH each
of which utilize decarboxylation reactions. Previous studies on
post-mortem AD brains indicate reduced levels and/or activity
of these key enzymes: PDH, αKGDH and IDH (Sorbi et al.,
1983; Butterworth and Besnard, 1990;Mastrogiacoma et al., 1996;
Gibson et al., 2000; Ko et al., 2001; Bubber et al., 2005), with
PDH and αKGDH exhibiting the largest decreases in activity.
Furthermore, Aβ peptides have been demonstrated to inhibit
PDH and αKGDH directly (Shearman et al., 1994; Casley et al.,
2002a,b). In contrast we find no change in the activity of the TCA
enzyme fumarase, the activity of which is also unaltered in AD
brains (Bubber et al., 2005). Our results add to these findings
by implicating raised BACE1 activity and manipulation of APP
processing as central to these enzyme deficits and metabolic
adaptations at the cellular level, indicating a key role for BACE1
and its up-regulation in response to oxidative and inflammatory
stress, which are associated with the very early stages of AD
(Nunomura et al., 2001; Zhang et al., 2007; Guglielmotto et al.,
2009). Indeed, these results show that raised BACE1 activity
effectively phenocopies some of the earliest changes in glucose
metabolism seen in the brain during the progression toward AD.
In situations of diminished glucose utilization, there are
a number of strategies that may be engaged in an attempt
to bypass this block in metabolism. For example, in brain
ischemic-reperfusion injury there is also decline in glucose
oxidation and PDH activity (Bogaert et al., 1994; Zaidan et al.,
1998). Application of glutamine has been demonstrated to
offer some protection against ischemic-reperfusion injury in
peripheral tissues by providing an alternative energy source for
the cell to maintain ATP content (Arsenian, 1998; Wischmeyer
et al., 2003). In addition to providing a source of carbon
for neurotransmitter production, glutamine can also feed into
the TCA cycle and be metabolized to increase levels of α-
ketoglutarate and succinate. However, our data demonstrate that
glutamine supplementation is unable to restore oxidative glucose
metabolism in cells overexpressing BACE1. Furthermore, SH-
SY5YB1 cells exhibited diminished oxidation of glutamine when
applied as sole substrate, in line with the reduced activity of
α-KGDH observed in these cells.
The inhibition of PDH activity in SH-SY5YB1 cells was
associated with increased phosphorylation of the e1α subunit at
Ser293, which is the main inhibitory site for PDH activity (Jha
et al., 2012). Although, PDK1 inhibition with dichloroacetate
reduced e1α phosphorylation levels, this was also observed in
SH-SY5YEV cells, in conjunction with a maintained relative
lower glucose oxidation in SH-SY5YB1 cells. This outcome may
be owing to the presence of BACE1 activity-sensitive DCA-
resistant PDK isoenzyme, or PDP, or an alternative kinase that
phosphorylates e1α at Ser293 (e.g. GSK3). In contrast, application
of the ketone, BHB, to SH-SY5YB1 cells demonstrates complete
recovery of glucose oxidation, relative to SH-SY5YEV cells,
presumably by directly increasing the availability of acetyl CoA
to the TCA cycle, thus circumventing PDH. The enhanced ability
to utilize ketone bodies to aid glucose oxidation in SH-SY5YB1
cells may result from their reduced BAD levels, compared to
SH-SY5YEV cells. This finding agrees with the work of Nikita
Danial’s group showing that neurons derived from BAD knock
out animals display an augmented bioenergetic profile in the
presence of ketone bodies (Giménez-Cassina et al., 2012).
α-lipoic acid is synthesized in mitochondria and is a
necessary cofactor for PDH and α-KGDH activity. Our finding
that exogenously applied α-lipoic acid also increases glucose
oxidation in SH-SY5YB1, but not SH-SY5YEV cells suggests that
raised BACE1 activity either reduces mitochondrial α-lipoic acid
levels or lessens the ability of α-lipoic acid to enhance PDH
and α-KGDH activity. The latter mechanism may be favored as
there is evidence that excess α-lipoic acid provides protection
to neuronal cells from the deleterious effects of exogenously
applied Aβ peptides on PDH activity (Bielarczyk et al., 2006)
and Aβ-induced toxicity (Zhang et al., 2001). Regarding the
potential to reverse the metabolic deficits associated with age-
dependent cognitive decline and early-stage or mild AD, the data
presented herein demonstrate the capacity of α-lipoic acid and
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 October 2015 | Volume 9 | Article 382
Findlay et al. BACE1 inhibits neuronal glucose oxidation
BHB to attenuate impaired glucose oxidation at a cellular level
in face of chronically raised BACE1 activity and increased levels
of Aβ peptides. BHB and α-lipoic acid have been demonstrated
to exhibit some positive effects on cognitive decline in elderly
dementia and mild AD patients (Hager et al., 2001; Reger et al.,
2004; Costantini et al., 2008; Henderson et al., 2009; Henderson
and Poirier, 2011).
Taken together, our findings are supportive for the rationale
of targeting these TCA enzyme deficits in early cognitive
impairment and AD. However, so far clinical trials based on
raising circulating levels of ketones or giving α-lipoic acid as a
dietary supplement have provided mixed outcomes and further
trials examining α-lipoic acid are currently in progress. Perhaps
a future strategy for AD management and treatment may be
through the combination of this neutraceutical approach with
new therapeutics, such as BACE1 inhibitors, currently in clinical
trials (Vassar et al., 2014).
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